Novozymes Biopharma Spotlights Innovative Solutions for Medical Devices, Drug Delivery and Formulation at CPHI 2010
Published: Sep 09, 2010
Novozymes' novel sodium hyaluronate is 100% free of animal-derived raw materials and organic solvent remnants and offers a range of benefits including increased safety, batch-to-batch consistency and stability in large scale. The product can be used within the pharmaceutical sector for improved drug delivery as well as in medical device application areas including ophthalmology, wound healing and dermal fillers. Derived from Novozymes' proprietary yeast expression technology, Recombumin® is the world's leading animal-free, commercially available recombinant human albumin. Offering the stabilizing benefits of albumin in a GMP compliant and regulatory package for medical devices, drug delivery and formulation, Recombumin ensures high performance and security of long term supply.
Peter Roshholm, vice president, Novozymes Biopharma comments: "Novozymes is delighted to be returning to CPhI following our success at the show over the past two years, winning Gold and Bronze innovation Awards in 2008 and 2009 respectively. This year the company will showcase its innovative biomanufacturing solutions which are helping customers to improve the efficiency of their processes. These proven solutions ensure improved consistency and a decreased regulatory burden while enabling the development of superior final products."
Novozymes will also be hosting a session entitled "Novozymes award winning cGMP sodium hyaluronate for medical device and drug delivery applications" during the show. The presentation is open to all delegates and will take place on October 6 at the CPhI Speaker's Corner located on the show floor.
To learn more about the company's solutions for drug delivery, formulation and medical devices, please visit Novozymes at booth #6L2 at CPhI Worldwide 2010. Alternatively please visit www.biopharma.novozymes.com
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.
Novozymes' natural solutions enhance and promote everything from removing trans fats in cooking, to advancing biofuels to power the world tomorrow.
Our never-ending exploration of nature's potential is evidenced by over 6,000 patents, showing what is possible when nature and technology join forces.
Our 5,000+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.
Contacts: Novozymes Biopharma: Sally Vernon, Customer Communications Manager SYKE@novozymes.com
Corporate Contacts: Press and media:
Johan Melchior Tel. (direct): +45 4446 0690 Tel. (mobile): +45 3077 0690
René Tronborg Tel. (direct): +45 4446 2274 Tel. (mobile): +45 3077 2274
Paige Donnelly (USA) Tel. (direct): +1 919 494 3209 Tel. (mobile): +1 919 218 4501
Investor relations: Tobias Bjørklund Tel. (direct): +45 4446 8682 Tel. (mobile): +45 3077 8682
Thomas Bomhoff (USA) Tel. (direct): +1 919 494 3483 Tel. (mobile): +1 919 649 2565